Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,516.00
Bid: 12,304.00
Ask: 12,600.00
Change: 0.00 (0.00%)
Spread: 296.00 (2.406%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,516.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-European shares rebound as Brexit trade deal progress overshadows virus worries

Tue, 22nd Dec 2020 10:05

(For a Reuters live blog on U.S., UK and European stock
markets, click LIVE/ or type LIVE/ in a news window)

* Britain-EU rifts over fishing narrow

* U.S. Congress approves $892 bln pandemic aid package

* Tech stocks, banks lead broad-based gains in Europe

* AstraZeneca slips as asthma drug fails in late-stage trial
(Updates to close)

By Susan Mathew

Dec 22 (Reuters) - European shares posted their best day in
six weeks on Tuesday, rebounding from a sharp sell-off as
optimism around Brexit and U.S. stimulus helped to allay worries
of a further hit to the global economy from a new coronavirus
variant in Britain.

The pan-European STOXX 600 index finished up 1.2%
on broad-based gains, recovering from a more than 2% slide in
the previous session, which was also its biggest one-day drop in
nearly two months.

The European Union is giving a "final push" in a bid to
strike a Brexit trade deal with Britain, its chief negotiator
said on Tuesday, with the two sides inching towards agreement on
fishing - a major sticking point - days before the end of
Britain's transition deal since it left the bloc.

"(The progress in fishing) highlights the willingness to
move towards something that will eventually break the current
deadlock," said Joshua Mahony, senior market analyst at online
trading platform IG.

Helping London's blue-chip index reverse early
losses, data showed Britain's economic recovery from its
coronavirus crash was quicker than previously thought in the
third quarter. The index closed 0.6% higher, breaking a
three-day losing streak.

The losses were triggered by the emergence of a
fast-spreading new coronavirus variant in Britain, which has
forced wider lockdowns there and led countries around the world
to close their borders to the UK. The EU on Tuesday recommended
rolling back border closures to allow freight to resume.

"The COVID-led economic isolation of the UK (is) serving to
provide a heavy dose of reality of the kind of disruption that
could come if negotiators fail to agree a (Brexit trade) deal by
year-end," Mahony said.

Technology stocks and Brexit-sensitive banks
led the rebound in Europe, while materials stocks lagged
as they tracked a decline in underlying commodity prices.

Meanwhile, U.S. President Donald Trump on Tuesday signed a
stopgap measure to fund U.S. agencies for another week after
Congress passed a long awaited $892 billion COVID-19 aid package
overnight.

AstraZeneca was the biggest weight on the pan-region
index, down 1.5% after its experimental asthma drug developed
with U.S partner Amgen failed to meet the main goal of
a late-stage trial.
(Additional reporting by Supriya R in Bengaluru; Editing by
Anil D'Silva and Mark Potter)

More News
3 Oct 2023 07:41

LONDON BRIEFING: Greggs sales rise; boohoo cuts revenue outlook

(Alliance News) - London's FTSE 100 is set to fall further on Tuesday, after a sell-off at the start of the week, with hawkish words from a US central banker reinforcing the 'higher-for-longer' interest rates messaging.

Read more
3 Oct 2023 07:24

AstraZeneca agrees to settle most Nexium, Prilosec claims

(Sharecast News) - Global pharmaceutical company AstraZeneca has agreed to settle litigation on product liability related to two of its widely-used heartburn drugs, Nexium and Prilosec, it announced on Tuesday.

Read more
25 Sep 2023 09:13

LONDON BROKER RATINGS: Jefferies raises AstraZeneca to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
25 Sep 2023 07:43

LONDON BRIEFING: Stocks seen lower; Aviva buys AIG's UK protection arm

(Alliance News) - Stocks in London were set to open lower on Monday as investors eyed fresh concerns for the already fragile Chinese property sector.

Read more
22 Sep 2023 08:42

LONDON MARKET OPEN: Stocks slip after central bank rate calls

(Alliance News) - Stock prices in London opened lower on Friday, but managed to avoid the steep declines seen in New York, as investors mulled over an eventful week dominated by central bank decisions.

Read more
22 Sep 2023 08:13

TOP NEWS: AstraZeneca's datopotamab deruxtecan shows positive results

(Alliance News) - AstraZeneca PLC on Friday said phase three data showed that datopotamab deruxtecan delivered improvement in progression-free survival in breast cancer patients.

Read more
22 Sep 2023 07:27

AstraZeneca reports positive findings from breast cancer threatment trial

(Sharecast News) - New high-level results from AstraZeneca's TROPION-Breast01 phase three trial, released on Friday, carried encouraging news for patients with inoperable or metastatic hormone receptor (HR)-positive, HER2-low or negative breast cancer.

Read more
20 Sep 2023 08:44

TOP NEWS: AstraZeneca's rare disease business buys Pfizer portfolio

(Alliance News) - AstraZeneca PLC on Wednesday said rare disease business Alexion has signed a purchase and licence agreement for a rare disease programme portfolio from Pfizer Inc.

Read more
15 Sep 2023 15:27

AstraZeneca and Daiichi Sankyo's Enhertu recommended for approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd's Enhertu has been recommended for approval in the EU on Friday.

Read more
14 Sep 2023 08:25

Smith & Nephew brings BT Chief Financial Officer Simon Lowth to board

(Alliance News) - Smith & Nephew PLC on Thursday announced that BT Group PLC's chief financial officer, Simon Lowth, will join the board as independent non-executive director on January 1.

Read more
11 Sep 2023 21:54

AstraZeneca says Fasenra therapy meets primary endpoint at trial

(Alliance News) - AstraZeneca PLC on Monday said that its therapy, Fasenra, met the primary endpoint in the Mandara phase three trial in eosinophilic granulomatosis with polyangiitis.

Read more
11 Sep 2023 10:17

UPDATE: AstraZeneca has good results from three cancer drugs in trials

(Alliance News) - AstraZeneca PLC reported positive clinical results of combinations of its Imfinzi and Tagrisso drugs with other treatments for lung cancer, while also seeing "strong and durable" tumour responses from its Enhertu antibody drug conjugate.

Read more
11 Sep 2023 07:54

LONDON BRIEFING: Restaurant Group sells Frankie & Benny's and Chiquito

(Alliance News) - Stocks in London are called higher on Monday, ahead of a busy week of interest rate decisions and economic data.

Read more
11 Sep 2023 06:59

AstraZeneca says Imfinzi and Tagrisso combinations show good results

(Alliance News) - AstraZeneca PLC reported positive clinical results of combinations of its Imfinzi and Tagrisso drugs with other treatments for cancer.

Read more
6 Sep 2023 09:36

AstraZeneca working with FDA on Ultomiris risk evaluation changes

(Alliance News) - AstraZeneca PLC on Wednesday said it is working closely with the US Food & Drug Administration regarding a request to changes to improve risk evaluation for Ultomiris.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.